Peter Bergman, M., Ola Blennow, M., Lotta Hansson, M., Stephan Mielke, M., Piotr Nowak, M., Puran Chen, M., . . . Soo Aleman, M. (2021). Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. Elsevier.
Style de citation Chicago (17e éd.)Peter Bergman, MD, et al. Safety and Efficacy of the MRNA BNT162b2 Vaccine Against SARS-CoV-2 in Five Groups of Immunocompromised Patients and Healthy Controls in a Prospective Open-label Clinical Trial. Elsevier, 2021.
Style de citation MLA (8e éd.)Peter Bergman, MD, et al. Safety and Efficacy of the MRNA BNT162b2 Vaccine Against SARS-CoV-2 in Five Groups of Immunocompromised Patients and Healthy Controls in a Prospective Open-label Clinical Trial. Elsevier, 2021.